AHA SCIENTIFIC STATEMENT

Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association

Gustavo Saposnik, MD, MPH, PhD, FAHA, Chair; Cheryl Bushnell, MD, MHS, FAHA, Vice Chair; Jonathan M. Coutinho, MD, PhD; Thalia S. Field, MD, MHSc; Karen L. Furie, MD, MPH, FAHA; Najibah Galadanci, MBBS, MPH, PhD; Wayneho Kam, MD; Fenella C. Kirkham, MD; Norma D. McNair, RN, PhD; Aneesh B. Singhal, MD, FAHA; Vincent Thijs, MD, PhD, FAHA; Victor X.D. Yang, MD, PhD; on behalf of the American Heart Association Stroke Council; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension

ABSTRACT: Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes. The most vulnerable populations include young individuals, women of reproductive age, and patients with a prothrombotic state. The clinical presentation of cerebral venous thrombosis is diverse (eg, headaches, seizures), requiring a high level of clinical suspicion. Its diagnosis is based primarily on magnetic resonance imaging/magnetic resonance venography or computed tomography/computed tomographic venography. The clinical course of cerebral venous thrombosis may be difficult to predict. Death or dependence occurs in 10% to 15% of patients despite intensive medical treatment. This scientific statement provides an update of the 2011 American Heart Association scientific statement for the diagnosis and management of cerebral venous thrombosis. Our focus is on advances in the diagnosis and management decisions of patients with suspected cerebral venous thrombosis. We discuss evidence for the use of anticoagulation and endovascular therapies and considerations for craniectomy. We also provide an algorithm to optimize the management of patients with cerebral venous thrombosis and those with progressive neurological deterioration or thrombus propagation despite maximal medical therapy.

Key Words: AHA Scientific Statements ■ anticoagulants ■ headaches ■ intracranial thrombosis ■ seizure ■ sinus thrombosis ■ venous thrombosis

Cerebral venous thrombosis (CVT) is the presence of a blood clot in the dural venous sinuses, the cerebral veins, or both.1 Among those with stroke, CVT represents only 0.5% to 3%.2 Registry-based and cohort studies suggest that CVT affects predominantly individuals <55 years of age, with two-thirds occurring in women.3 With regard to location, the most commonly affected sinuses are illustrated in Figure 1.1–3 Overall, patients with CVT have a favorable outcome. Most patients with CVT nowadays survive without physical disability, but chronic symptoms, which negatively affect quality of life, are not uncommon. Most common factors associated with poor prognosis include advanced age, active cancer, decreased level of consciousness, and intracerebral hemorrhage, among others.1,4,5

This scientific statement synthetizes the clinical presentation, predisposing factors, advances in imaging modalities and therapies, and management of CVT in special populations (pediatric, pregnancy and puerperium, and vaccine-induced CVT). This document is strengthened by new evidence since our previous publication in 2011.1 Future areas of research are highlighted.

CLINICAL PRESENTATION

Presenting symptoms of CVT can be due to increased intracranial pressure or focal parenchymal injury, with or without mass effect.1 Headache is the most common symptom of CVT, occurring in nearly 90% of cases.4 Other signs and symptoms related to intracranial
Prevalence of sinus involvement in CVT. Percentages may be >100% because many patients may have >1 sinus involved. Please note that internal jugular vein thrombosis represents its concomitant prevalence with CVT (not in isolation). CVT indicates cerebral venous thrombosis.

Predisposing factors for CVT are identified in the majority of those with the disease and may be transient or chronic (Table). Rates of CVT are highest in younger women, with both oral contraception and pregnancy/puerperium being major risk factors. Oral contraception and hormonal therapies (primarily those containing estrogen-based formulations) may increase the odds of CVT nearly 8-fold, with possible additional synergistic effects with obesity. Other well-established risk factors include acquired thrombophilias such as antiphospholipid antibody syndrome, JAK2 mutations, malignancy, particularly myeloproliferative disorders, and autoimmune disease, including Behçet and inflammatory bowel disease. Genetic thrombophilias such as protein C and protein S deficiency, factor V Leiden, and prothrombin G20210A polymorphism can be associated with CVT. Other transient provoking factors commonly reported in previous series include infections (COVID-19, head and neck infections), dehydration, other medications such as corticosteroids and L-asparaginase, and vaccine-induced thrombotic thrombocytopenia (VITT). Mechanical provoking factors such as head trauma, neurosurgical procedures, and compressive lesions such as meningiomas impinging on venous sinuses are also associated with CVT.

LONG-TERM SYMPTOMS AND CVT RECURRENCE

Overall, 80% to 90% of patients with CVT achieve functional independence (modified Rankin Scale score of 0–2). However, several studies reported a high prevalence of residual symptoms related to cognition, mood, fatigue, and headache, which may impede return to previous level of activity. A prospective cohort from a Canadian randomized trial found that although 72% of individuals with CVT remained functionally independent at the time of their presentation, there was an overall substantial burden of headache, fatigue, low mood, and impaired cognitive performance. A retrospective study from China including 303 patients with CVT who were employed or students before their index event found that 42% had not returned to work or school at 6 months, despite 87% reaching functional independence at the time of assessment.

Epilepsy may affect >10% of individuals with CVT, with risk factors including seizures at the time of onset, decreased level of consciousness or focal deficits,
hemorrhagic lesions at baseline or superior sagittal sinus involvement, and craniectomy. Dural arteriovenous fistula is a reported complication of CVT, but CVT can also be a sequela of dural arteriovenous fistula. A large retrospective series of 1218 individuals with CVT found a prevalence of new dural arteriovenous fistula of 2.4% at a median follow-up of 8 months (interquartile range, 5–23 months), although no systematic timing or neuroimaging protocol was included in the study. A prospective study with systematic imaging collection at 6 months after CVT found no dural arteriovenous fistula.

The incidence of recurrent venous thromboembolism (VTE) after CVT ranges from 1% to 4% per year, with rates of CVT recurrence generally reported as <1% to 2% per year. A higher risk of recurrence has been reported in individuals with severe thrombophilia (including malignancy), those with a history of VTE, individuals with events without identified precipitants, and, inconsistently, male individuals. A secondary analysis of ACTION-CVT (Anticoagulation in the Treatment of CVT) showed a VTE recurrence of 6.4% (2.5% for CVT recurrent alone although brain images were not centrally adjudicated). A recent retrospective study of VTE recurrence (including CVT) reported rates of 5.68 per 100 patient-years, more than half of which were CVT.

A study from Norway found that individuals with CVT (n=654; median age, 41 years; 67% women) compared with general population age- and sex-matched control subjects were at increased risk of recurrent VTE, ischemic stroke, major bleeding, and mortality at 10 years. Risks of recurrent VTE were higher in younger individuals (age, 18–54 years) with CVT compared with the general population, whereas risks of ischemic stroke, major bleeding, and mortality (risk difference, 11.5% for women ≥55 years of age and 5.8% for men ≥55 years) were highest in older patients.

### BRAIN AND VASCULAR IMAGING FOR THE DIAGNOSIS OF CVT

Conventional computed tomography (CT) or magnetic resonance imaging (MRI) is often the first test obtained in patients with nonspecific acute presentations and may...
show signs that increase suspicion for CVT. For example, CVT on CT or MRI may be suspected by (1) direct visualization of the thrombus, (2) the absence of venous filling, and (3) imaging of the consequences of venous obstruction at the tissue level (venous infarction, edema and hemorrhagic transformation, intracranial hypertension and hydrocephalus) and at the vascular level (dilated veins). Common challenges of brain imaging are summarized in Supplemental Table 2.

Direct imaging of thrombus is possible on CT, especially with the increased use of thin-slice CT (Figure 2A–2D). On noncontrast CT this is observed as hyperattenuation due to increase of hemoglobin and red blood cells within the thrombus (dense vessel sign; Figure 2B–2E). The traditional cord or string sign, a serpiginous or linear hyperdensity within a vein, or dense triangle sign can be present up to 14 days after onset of symptoms (Figure 2E). Indirect signs that raise the suspicion on noncontrast CT (and MRI) include areas of hypodensity not conforming to typical wedge-shaped infarctions or that are not limited to specific arterial territories or sparing the overlying cortex. Bilateral hypodensities may occur when the sagittal sinus or deep cerebral veins are involved. Hemorrhages are present in up to 40% of CVT and include areas of hemorrhagic transformation within regions of hypodensity or frank intracerebral hemorrhage associated with subarachnoid or subdural hemorrhages. Isolated subarachnoid and basal ganglia hemorrhages are uncommon. The cashew nut sign, a juxtacortical C-shaped hyperdensity, is reported to have a high specificity for CVT but has low sensitivity (Figure 2A). Bilateral or multifocal hemorrhages also occur frequently (Figure 2F). In a recent meta-analysis of 27 publications with 2812 cases, CT had a sensitivity of 0.79 (95% CI, 0.76–0.82) and specificity of 0.90 (95% CI, 0.89–0.91) lower than previously reported in the 2011 American Heart Association statement.

Thrombi can also be directly observed on conventional MRI sequences (Figure 3). Because the evolution of a thrombus on MRI is dynamic, changes in the signal intensity of the thrombus over time are similar to that of a hematoma. As the thrombus ages, oxyhemoglobin is converted to deoxyhemoglobin and met-hemoglobin, leading to changes in signal characteristics on the T1 and T2 sequences. In these early stages, it is difficult to diagnose thrombosis because T2 may be isointense or hypointense, mimicking a normal flow void of a venous sinus. Similarly, time-of-flight magnetic resonance venography (MRV) is susceptible to misdiagnosis because absent flow is not always corroborated on T1/T2 sequences (Supplemental Table 2). Consequently, it is often helpful to corroborate findings with gradient-recalled echo, susceptibility-weighted imaging sequences, or contrast-enhanced MRV. Thrombosed blood creates a blooming artifact on gradient-recalled imaging.
echo or susceptibility-weighted imaging sequences that is especially useful in the identification of inconspicuous findings (Figure 3B) such as thrombosed cortical veins, where they have a sensitivity and specificity approaching 100%. Advanced MRI techniques such as T1-based black-blood imaging (in which signal from flowing blood is suppressed) are promising. MRI is more sensitive than CT in the detection of parenchymal brain lesions secondary to venous occlusion such as venous infarctions (in which signal from flowing blood is suppressed) are promising. MRI is more sensitive than CT in the detection of parenchymal brain lesions secondary to venous occlusion such as venous infarctions (in which signal from flowing blood is suppressed) are promising.

A meta-analysis of 21 studies with 1773 patients with CVT showed conventional MRI sequences to have a sensitivity of 0.82 (95% CI, 0.78–0.85) and specificity of 0.92 (95% CI, 0.91–0.94). Compared with 3-dimensional TOF, 2-dimensional TOF has higher sensitivity in the setting of slow flow. Phase-contrast MRI is used less frequently because defining the velocity of the encoding parameter is not only difficult but operator dependent and requires longer acquisition times. Contrast-enhanced MRV has a sensitivity and specificity comparable to that of CTV but allows better characterization between the low-flow state and hypoplastic

**CONFIRMING THE DIAGNOSIS OF CVT**

CT venography and MRV are the optimal tests to confirm a diagnosis of CVT. Digital subtraction angiography is typically used only when invasive treatments are considered.

CT venography allows clear depiction of the superficial and deep cerebral venous system. Thrombi present as filling defects (*empty delta sign* referred to the superior sagittal sinus) and can usually be easily distinguished from arachnoid granulations. Several small to moderately sized studies have demonstrated a high sensitivity and specificity of CTV compared with digital subtraction angiography or a consensus reading of other imaging modalities. Compared with MRI, CTV has a lower sensitivity for cortical vein thrombosis.

MRV (Figure 3) can be performed without contrast, with time-of-flight (TOF) or phase-contrast techniques, or with a contrast-enhanced technique (Figure 3E and 3F). The use of gadolinium with contrast-enhanced technique allows direct assessment of luminal filling and increases the sensitivity of the detection of thrombus within the smaller veins. Both TOF and phase-contrast MRV techniques can be prone to artifact secondary to complex flow. TOF is, however, still commonly used and is especially useful in situations that may preclude gadolinium administration such as in pregnant or breastfeeding patients or in patients with severe renal failure. Compared with 3-dimensional TOF, 2-dimensional TOF has higher sensitivity in the setting of slow flow. Phase-contrast MRI is used less frequently because defining the velocity of the encoding parameter is not only difficult but operator dependent and requires longer acquisition times. Contrast-enhanced MRV has a sensitivity and specificity comparable to that of CTV but allows better characterization between the low-flow state and hypoplastic
sinus (flow gaps). Contrast-enhanced techniques and gradient-recalled echo or susceptibility-weighted imaging are recommended for diagnosing cortical vein thrombosis (new evidence since the 2011 American Heart Association statement).  

THERAPEUTIC ADVANCES IN THE MANAGEMENT OF CVT

Oral Anticoagulation

The objectives of anticoagulation therapy in CVT are to prevent thrombus growth, to facilitate recanalization, and to prevent recurrent VTE events. Previous American Heart Association/American Stroke Association and European guidelines for the management of CVT recommend the initial use of low-molecular-weight heparin (LMWH) over unfractionated heparin followed by transition to oral vitamin K antagonists (VKAs) for 3 to 12 months in the context of transient risk factors or indefinitely in the context of chronic major risk factors for thrombosis or recurrent VTE (Figure 4). LMWH is favored in the acute treatment of CVT given the more practical administration, more predictable anticoagulation effect, lower risk of thrombocytopenia, and trends toward better outcomes in meta-analyses that do not meet the threshold for statistical significance. The presence of venous hemorrhage does not constitute a contraindication for anticoagulation. Whether degree of venous recanalization should inform duration of anticoagulation remains an area of uncertainty.

An emerging body of evidence suggests that direct oral anticoagulants (DOACs), which have demonstrated efficacy and safety compared with VKA for individuals with deep venous thrombosis and pulmonary embolism, may also be a reasonable choice for oral anticoagulation in selected individuals with CVT.

RE-SPECT CVT (A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etxelxilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis) was an international prospective clinical trial that randomized 120 individuals with CVT 1:1 to warfarin VKA with target international normalized ratio of 2.0 to 3.0 or dabigatran 150 mg twice daily for 6 months after 5 to 15 days of lead-in parenteral anticoagulation. The trial excluded individuals with malignancy, those with antiphospholipid antibody syndrome, and those who were pregnant. The study found no significant difference in rates of recurrent VTE (adjusted hazard ratio, 0.94 [95% CI, 0.15–1.73]), and there was a reduced risk of major hemorrhage (adjusted hazard ratio, 0.35 [95% CI, 0.15–0.82]), driven primarily by a lower risk of intracerebral hemorrhage, in the DOAC group. There were no differences in recanalization rates between groups in either study.

A recent systematic review summarizing 3 randomized trials and 16 observational studies comparing DOACs with VKAs found similar rates with both treatments of recurrent VTE, major hemorrhage, and complete recanalization (42.9% versus 42.3%; relative risk, 0.98 [95% CI, 0.87–1.11]).

From the current available evidence, it is reasonable to transition to DOAC or VKA after a period of lead-in parenteral anticoagulation, but whether 5 to 15 days is a safer or more effective strategy than shorter periods is not known.

Additional clinical trials and prospective observational studies are ongoing (ClinicalTrials.gov NCT03178864, NCT04660747). Persistent areas of controversy include timing of initiation with or without lead-in heparin, whether acute VTE dosing is initially required, and optimal candidates for DOAC therapy. DOACs are not suitable in women who are pregnant (both DOAC and warfarin are contraindicated; only LMWH is recommended) or breastfeeding (DOACs are contraindicated; Figure 4). DOACs have also been associated with higher risks of recurrent thromboembolic events compared with warfarin in individuals with antiphospholipid antibody syndrome. For patients with cancer, DOACs were at least noninferior to LMWH in the prevention of VTE. There is limited evidence of the role of antiplatelet agents after discontinuation of oral anticoagulation in CVT. Studies focused on secondary prevention of VTE showed that aspirin was more effective than placebo (hazard ratio, 0.68 [95% CI,
0.51–0.90; \( P=0.008 \)). Compared with all comers with VTE, those with CVT are younger and thus would have a longer lifetime exposure to aspirin. In addition, the CVT literature describing longer-term recurrence risk of VTE is less robust. Thus, potential benefits should be carefully considered along with individual patient characteristics in shared decision-making.

**Reperfusion Therapies**

Endovascular treatment (EVT) options for the management of CVT could theoretically offer faster recanalization, although any association with a more favorable outcome in medical therapy, particularly in an unselected population, is uncertain. Several studies in the past decade that reported the use of mechanical thrombectomy (either balloon assisted or through aspiration or vacuum aspiration systems), intrasinus thrombolysis, combination of mechanical thrombectomy and intra-sinus thrombolysis, intra-arterial thrombolysis, and intra-sinus stenting provide controversial evidence on safety and complication rates. The multicenter, randomized clinical TO-ACT trial (Thrombolysis or Antiocoagulation for CVT) showed that patients with severe CVT did not benefit clinically from EVT compared with the patients receiving standard antiocoagulation therapy. Larger studies and meta-analyses showed that EVT is associated with higher mortality and no evidence of benefit with EVT.
Currently, EVT is used as a rescue treatment for patients who are experiencing clinical deterioration or failed or have contraindications to standard therapy (Figure 4). In a systematic review including 10 studies comprising 339 patients who underwent EVT for CVT, the authors found a complete and partial postoperative recanalization in 90.0% of patients, increasing to 95.2% during the follow-up. The complication rate was 10.3%. There is no current evidence to determine which EVT technique (eg, stent retriever, microcatheters, aspiration catheters, aspiration pump systems) is superior to other therapeutic strategies.

Decompressive Craniectomy

The evidence on decompressive craniectomy for CVT remains unchanged since the previous American Heart Association statement. It should be offered to patients with acute severe CVT and parenchymal lesions with impending herniation as a lifesaving therapeutic approach (Figure 4). Factors associated with poorer outcomes included age >50 years, midline shift >10 mm, and total effacement of basal cisterns. There are no randomized controlled trials of this surgical approach in the literature. A systematic review and meta-analysis including 51 studies comprising 483 patients with CVT showed that surgery within 48 hours of admission may decrease mortality (odds ratio [OR], 0.26 [95% CI, 0.10–0.69]) and result in improved functional outcomes.

CVT IN SPECIAL POPULATIONS

Pediatric Population

CVT is more common in neonates (6.4/100 000) than in children and adolescents. The key to successful management is to consider the diagnosis early in acute presentations with headache, seizures, focal neurological deficits, or coma and in typical situations such as sepsis (including mastoiditis, Lemierre syndrome, COVID-19, and meningitis), head trauma (including abuse), hypoxia, and dehydration. Awareness is especially important in children with preexisting conditions (congenital heart disease and its surgical treatment, cancer and its treatment, anemia due to iron deficiency or hemoglobinopathies, and inflammatory conditions, eg, nephrotic syndrome and inflammatory bowel disease). Emergency imaging to diagnose or exclude dural or cortical venous thrombosis with or without parenchymal involvement or hemorrhage typically requires anesthestia. Initial blood work may reveal low platelets associated with platelet factor 4 mutations or high platelets and high hemoglobin associated with JAK2 mutations, as well as indices of iron deficiency with or without anemia.

The management of acute CVT in children typically involves LMWH or unfractionated heparin. As for adults, if there is deterioration in level of consciousness, more invasive procedures should be considered and may potentially be lifesaving (Figure 4). Anticoagulation in the acute phase is more controversial in premature and term neonates but is reasonable because there is no evidence of posttreatment hemorrhage, whereas lack of anticoagulation may lead to thrombus propagation. CVT in children carries a mortality rate of 3%, and recurrent venous thrombosis occurs in ≈6%, usually associated with no administration of anticoagulation and lack of venous recanalization. Since the prior scientific statement, there have been randomized trials on duration of anticoagulation and the use of DOACs. In individuals 4 months to 20.9 years of age, the Kids-DOTT trial (Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children) compared 6 weeks with 3 months of anticoagulation for provoked VTE (including 59/417; 25% patients with CVT). Six weeks of anticoagulation was noninferior for recurrent VTE and bleeding events.

In the EINSTEIN-Jr trial (Oral Rivaroxaban in Children With Venous Thrombosis), after initial heparinization, 114 children with confirmed CVT were randomized (2:1) to 3 months of rivaroxaban or standard anticoagulation (continuing heparin or switching to oral VKAs). The primary efficacy outcome was symptomatic recurrent VTE, and the principal safety outcome was major or clinically relevant nonmajor bleeding. With 100% follow-up, none of the 73 children treated with rivaroxaban compared with 1 of the 41 children treated with standard anticoagulation had symptomatic recurrent VTE (absolute difference, 2.4% [95% CI, −2.6% to 13.5%]). Five patients on rivaroxaban had nonmajor and noncerebral bleeding, whereas 1 patient on standard anticoagulation had a major subdural bleed. Complete or partial recanalization occurred in 18 (25%) and 39 (53%) patients on rivaroxaban and 6 (15%) and 24 (59%) patients on standard anticoagulation. No children died by the end of the 3-month study treatment period. Focal neurological deficits were observed in 5 (6.8%) and 3 (7.3%) children in the rivaroxaban and standard anticoagulation group, respectively, at the end of the study. However, other long-term studies suggest that despite treatment 1 in 4 children may develop late epilepsy, infantile spasms after neonatal CVT, cognitive impairment, or intracranial hypertension.

CVT During Pregnancy and Puerperium

Pregnancy induces changes in the coagulation system that persist into the puerperium and result in a hypercoagulable state, increasing the risk of CVT. Incidence estimates during pregnancy and the puerperium range from 1 in 2500 deliveries to 1 in 10 000 deliveries in Western countries, and ORs range from 1.3 to 13.0. The greatest risk periods for CVT include the third trimester and the first 6 postpartum weeks. Approximately 80% of pregnancy-related CVT cases occur after delivery.
case-control study found that the risk is increased only in the puerperium (OR, 10.6 [95% CI, 5.6–20.0]), whereas there was no statistically significant increased risk of CVT during pregnancy (OR, 1.2 [95% CI, 0.6–2.3]). Cesarean delivery appears to be associated with a higher risk after adjustment for age, vascular risk factors, presence of infections, hospital type, and location (OR, 3.10 [95% CI, 2.26–4.24]). Overall, studies published since the prior scientific statement have found that the prognosis for women with pregnancy-related CVT is better than or the same as that for patients with CVT in general.

VKAs, including warfarin, are associated with fetal embryopathy and bleeding in the fetus and neonate and thus are contraindicated in pregnancy. Therefore, anticoagulation for CVT during pregnancy and early in the puerperium consists of LMWH in the majority of women. There is limited evidence on endovascular therapies in this population. As in nonpregnant women, thrombolysis and thrombectomy are reserved for patients with neurological deterioration or propagation of the thrombus despite medical therapy (Figure 4).

Future Pregancies and Recurrence

Women with a history of VTE appear to have an increased risk of thrombotic events (ie, deep venous thrombosis, pulmonary embolism) in future pregnancies. A systematic review comprising 17 studies and 393 pregnancies found a recurrence rate of 8 per 1000 pregnancies (95% CI, 3–22). The rate of noncerebral VTEs was 22 per 1000 pregnancies (95% CI, 11–43). There was a trend toward a lower rate of recurrent thrombotic events in women who used antithrombotic prophylaxis.

According to the available evidence, CVT is not a contraindication for future pregnancies. Considering the additional risk that pregnancy confers to women with a history of CVT, prophylaxis with LMWH during future pregnancies and the postpartum period is probably beneficial.

VITT and CVT

In 2021, reports from Europe and the United States described thrombocytopenia and CVT after vaccination with the ChAdOx1 nCoV-19 vaccine (AstraZeneca) and the Ad26.COV2.S adenovirus-based SARS-CoV-2 vaccine (Janssen). The age range of affected patients was 18 to 77 years; most were women. Symptoms began 5 to 24 days after vaccination. Headache was the most common presenting feature. All patients had thrombocytopenia. In the United Kingdom, 23 patients with antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination were described. It is believed that DNA from the adenovirus-infected cells bonded to platelet factor 4 and triggered the production of autoantibodies. Although CVT in VITT is a rare condition, it carries a poor prognosis, with mortality rates ranging from 39% to 61% in initial cohort studies. A study on the global impact of COVID-19 that included 2313 CVT admissions across 1 prepandemic year (2019) and 1 pandemic year (2020) found 26 cases of VITT, resulting in 6 deaths. A diagnosis of COVID-19 infection was present in 7.6% of all CVT admissions.

A pharmacovigilance study comprising >1.7 million adverse reactions showed a disproportionately lower incident risk of CVT after vaccination with mRNA SARS-CoV-2 vaccines compared with adenovirus-based SARS-CoV-2 vaccines (1–5/10 000 for BNT162b2 and mRNA-1273 versus 13/10 000 for ChAdOx1 nCoV-19 vaccine). In addition, there is no evidence of VITT after mRNA vaccines.

In cases of suspected VITT, laboratory testing for platelet factor 4 antibodies is recommended. Despite the lack of evidence, given the similarity to autoimmune heparin-induced thrombocytopenia, avoidance of heparin products, intravenous immunoglobulin 1 g/kg body weight daily for 2 days, and administration of steroids have been advised. Platelet transfusions are not recommended. Nonheparin parenteral anticoagulants (argatroban, fondaparinux) are typically used first, with transition to an oral anticoagulant (ie, DOAC) once there is full platelet count recovery.

KEY POINTS FOR CLINICAL PRACTICE

- CVT requires a high level of suspicion among patients presenting with common symptoms and known predisposing conditions (pregnancy, puerperium, use of oral contraceptives, thrombophilia) or demographic factors (young women).
- New predisposing conditions (obesity, COVID-19, vaccine-induced thrombocytopenia) were identified since our previous report.
- MRI/MRV is the recommended noninvasive study of the cerebral venous system to confirm the diagnosis. CT/CTV is a reasonable alternative in centers with limited resources or if the pretest probability is low.
- Contrast-enhanced MRV, gradient-recalled echo, or susceptibility-weighted imaging sequences are the recommended techniques for the diagnosis of cortical venous thrombosis.
- The mainstream initial treatment of CVT includes parenteral heparin followed by transition to oral VKAs for 3 to 12 months, depending on the underlying cause, or indefinitely in the presence of thrombophilia or recurrent VTE (Figure 4).
- DOACs appear to be a safe and effective alternative option to VKAs according to open-label retrospective and prospective randomized studies.
- The strategy of identifying venous recanalization in subsequent CTV or MRV to guide the duration of anticoagulation remains uncertain.
- Given the lack of controlled studies (and poorer outcomes in meta-analyses), endovascular therapies
are reserved for patients with evidence of thrombus propagation, for individuals with neurological deterioration despite medical therapy, or for those with contraindications to anticoagulation (Figure 4). (New)

- Despite the low level of evidence, decompressive surgery is a lifesaving procedure that may result in improved functional outcomes among patients with advanced clinical signs of herniation. (New)

- For women with CVT during pregnancy, LMWH in full anticoagulant doses should be continued throughout pregnancy, and LMWH or VKA with a target international normalized ratio of 2.0 to 3.0 should be continued for at least 6 weeks postpartum (for a total minimum duration of therapy of 3 months).

- It is reasonable to advise women with a history of CVT that future pregnancy is not contraindicated. Prophylaxis with LMWH during future pregnancies and the postpartum period is usually recommended.

- CVT in the pediatric population is more common in neonates than children, usually among those exposed to infections, dehydration, iron deficiency, anemia, or head trauma. Parenteral anticoagulation is also the first-line treatment, followed by LMWH, VKA, or rivaroxaban for at least 6 weeks.

- VITT and CVT may occur (rarely) days or a few weeks after an individual receives adenosine-based SARS-CoV-2 vaccines, usually presenting with new onset of headaches and thrombocytopenia; it requires the expert management of a hematologist and multidisciplinary team. (New)

**Disclosures**

**Writing Group Disclosures**

<table>
<thead>
<tr>
<th>Writing group member</th>
<th>Employment</th>
<th>Research grant</th>
<th>Other research support</th>
<th>Speakers’ bureau/honoraria</th>
<th>Expert witness</th>
<th>Ownership interest</th>
<th>Consultant/ advisory board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gustavo Saposnik</td>
<td>St Michael’s Hospital, University of Toronto (Canada)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cheryl Bushnell</td>
<td>Wake Forest School of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jonathan M. Coutinho</td>
<td>Amsterdam UMC, University of Amsterdam (Netherlands)</td>
<td>Bayer**, AstraZeneca**, Dutch Heart Foundation (nonprofit organization)<strong>, Dutch Thrombosis Foundation (nonprofit organization)</strong>, ZonMw (nonprofit government organization)**; All fees paid to his employer for all.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>TrianeCT*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Thalia S. Field</td>
<td>University of British Columbia Centre for Brain Health (Canada)</td>
<td>Canadian Institutes of Health Research (research grant to her institution)<strong>; Heart and Stroke Foundation of Canada (research grant to her institution)</strong>; Bayer Canada (m-kind study medication)**</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Canadian Medical Protective Association*</td>
<td>DESTINE Health*</td>
<td>None</td>
</tr>
<tr>
<td>Karen L. Furie</td>
<td>Rhode Island Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Writing Group Disclosures Continued

<table>
<thead>
<tr>
<th>Writing group member</th>
<th>Employment</th>
<th>Research grant</th>
<th>Other research support</th>
<th>Speakers’ bureau/ honoraria</th>
<th>Expert witness</th>
<th>Ownership interest</th>
<th>Consultant/advisory board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Najibah Galadanci</td>
<td>University of Alabama at Birmingham</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Wayneho Kam</td>
<td>Duke University Hospital; UNC Health Rex Comprehensive Stroke Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Fenella J. Kirkham</td>
<td>UCL GOSH Institute of Child Health (United Kingdom)</td>
<td>Action Medical Research (RCT of Montelukast in SCD with processing speed end point)†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer† UCL (professor of pediatric neurology)†</td>
</tr>
<tr>
<td>Norma D. McNair</td>
<td>Retired Nursing</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Anesh B. Singhal</td>
<td>Massachusetts General Hospital</td>
<td>MGH Fireman Vascular Center (SPARK Award)*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>MedicalLegal expert witness*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vincent Thij</td>
<td>Florey Neurology (Australia)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Victor X. D. Yang</td>
<td>Sunnybrook Health Sciences Center (Canada)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.  

"Modest.  
†Significant.

### Reviewer Disclosures

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Employment</th>
<th>Research grant</th>
<th>Other research support</th>
<th>Speakers’ bureau/ honoraria</th>
<th>Expert witness</th>
<th>Ownership interest</th>
<th>Consultant/advisory board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ekaterina Bakradze</td>
<td>University of Alabama at Birmingham</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>José Ferro</td>
<td>Faculdade de Medicina, Universidade de Lisboa (Portugal)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Matthew Frosch</td>
<td>Massachusetts General Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hans-Christian Koennecke</td>
<td>Vivantes Klinikum im Friedrichshain (Germany)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medical guidelines (I am a member of the writing group for guidelines for cerebral venous thrombosis of the Deutsche Gesellschaft für Neurologie [German Neurological Society])†</td>
</tr>
<tr>
<td>Thanh Nguyen</td>
<td>Boston University Chobanian and Avedisian School of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Idorsia*</td>
</tr>
<tr>
<td>Brian Silver</td>
<td>UMass Memorial Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kori Zachrison</td>
<td>Massachusetts General Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.  

"Modest.  
†Significant.
57. Saposnik et al Diagnosis and Management of Cerebral Venous Thrombosis